

UNCLASSIFIED

AD NUMBER
ADB266081
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Information; Jul 2000. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, MD 21702-5012
AUTHORITY
USAMRMC ltr, dtd 10 Jun 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-98-1-8216

TITLE: Determination of Catechol Estrogen Adducts by High-
Performance Liquid Chromatography: Establishing
Biomarkers for the Early Detection of Breast Cancer

PRINCIPAL INVESTIGATOR: Douglas E. Stack, Ph.D.

CONTRACTING ORGANIZATION: University of Nebraska at Omaha
Omaha, Nebraska 68182-0210

REPORT DATE: July 2000

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, Jul 00). Other requests
for this document shall be referred to U.S. Army Medical Research
and Materiel Command, 504 Scott Street, Fort Detrick, Maryland
21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20010509 062

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-98-1-8216

Organization: University of Nebraska at Omaha

Location of Limited Rights Data (Pages):

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Mandarmy

04/05/01

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2000	3. REPORT TYPE AND DATES COVERED Annual (1 Jun 99 - 1 Jun 00)	
4. TITLE AND SUBTITLE Determination of Catechol Estrogen Adducts by High-Performance Liquid Chromatography: Establishing Biomarkers for the Early Detection of Breast Cancer			5. FUNDING NUMBERS DAMD17-98-1-8216	
6. AUTHOR(S) Douglas E. Stack, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Nebraska at Omaha Omaha, Nebraska 68182-0210 E-MAIL: destack@unomaha.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Jul 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) In order to better understand the role of estrogen metabolism as it relates to breast cancer etiology, a new analytical technique that can measure CE and CE-DNA adducts at low endogenous levels is being developed. This new technique is based on HPLC analysis of fluorescent probes specific for CE and CE-DNA adducts. Reaction of α,α -dibromomalonates occurs quickly with catechols, and this malonate system is being developed to produce fluorescent probes for HPLC analysis. Synthesis of bis-(9-methylene-fluorenyl) α,α -dibromomalonate and its reaction with catechol and 4-OHE ₁ produced fluorescent products whose emission was red-shifted from 315 to 455 nm. This red-shift was also accompanied by reduced quantum yield that limits the sensitivity of the fluorenyl malonate probe. This derivation was also analyzed by fluorescence line narrowing spectroscopy (FLNS) to see if structural differences could be observed. FLNS showed that small changes in A ring environments of catechol and 4-OHE ₁ could be detected. In order to increase the sensitivity of malonate derived CE, bis-(9-methyleneanthranyl) α,α -dibromomalonate was synthesized. Reaction of the anthranyl malonate probe with CE is ongoing. The long-term goal for developing this new analytical assay is the establishment of biomarkers for the early detection of breast cancer.				
14. SUBJECT TERMS Breast Cancer, Biomarkers, Estrogen Metabolism			15. NUMBER OF PAGES 13	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

 Where copyrighted material is quoted, permission has been obtained to use such material.

 Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

 Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


PI - Signature

6/30/00
Date

INTRODUCTION:

The metabolism of estrogen to procarcinogenic catechols has been hypothesized as an initiation step in the development of breast cancer [1-4]. Specifically, the over expression of 4-hydroxylase activity has been observed in organs prone to estrogen-induced tumors [5-8]. The role of 4-hydroxyestradiol (4-OHE₂) and 4-hydroxyestrone (4-OHE₁) metabolites with the increase occurrence of estrogen-induced tumors is still not clear. Hypothesis regarding redox-cycling [9-13] and oxidation to electrophilic quinones have been examined [3,4]. Since oxidation of catechol estrogens (CE) to catechol estrogen quinones (CE-Q) has been shown to lead to CE-DNA adducts [4], we seek to develop an analytical technique that can measure these adducts at biologically meaningful, endogenous levels. The purpose of developing this assay is to examine whether CE-DNA adducts are present in breast cancer tissue. This would be a first step in understanding the etiology of breast cancer as it relates to estrogen metabolism; specifically, the role of 4-hydroxylase activity in the increase occurrence of estrogen-induced cancers. The scope of this method development involves the production of fluorescent probes, specific for the catechol moiety, so that ultra, low-level detection of these adducts can be accomplished. With the proper development of fluorescent probes, this assay would not only be very sensitive, but selective towards the oxidatively liable CE-DNA adducts.

BODY:

Our work the past year was focused on accomplishing Task 2, "Develop an HPLC analytical procedure, via pre-column fluorescence derivation, for the femtomolar detection of CE-adducts, CE, and MPEM in human breast tissue". The production of novel *gem*-dihalides, reactive towards the catechol moiety, was advanced in order to find a fluorescence probe that would not only allow for sufficient sensitivity, but also help to identify estrogen metabolites. Since the completion of Tasks 1 and 3 depends on this analytical probe, we have spent our efforts engineering a probe that will significantly advance the technology of detecting CE metabolites and CE-DNA adducts in human tissue.

The production of a new fluorescent probe specific for the catechol moiety requires the consideration of several issues. Quantum yields for fluorescent molecules are highest in ridged systems with minimal conformational flexibility near the fluorescent emitting portion of the molecule [9]. The binding of both phenol hydroxy groups onto a single atom generates a new ring system with reduced conformational flexibility when compared to the binding of two separate fluorescent probes (Figure 1). Thus, the design of our new probe was conducted with several features in mind. First, a highly fluorescent fluorophore was selected to maximize sensitivity. Second, the fluorophore should be attached to an atom bearing two electrophilic leaving groups so that reaction with both nucleophilic phenol hydroxy groups could take place leading to the formation of a five membered ring. Third, the atom possessing the two electrophilic leaving groups could not be prochiral because formation of a new chiral center would produce a mixture of diastereomeric products (since the estrogen ring system is chiral), complicating separation and quantitation of CE-DNA adducts. Fourth, the reaction with phenols should take place in near quantitative fashion, under mild conditions, in solvents conducive to reverse phase HPLC. Also, if the probe is design in a manner that allows interaction between the CE A ring and the fluorophore, fluorescence line narrowing spectroscopy (FLNS) can be used to identify the metabolite based on standard spectra.

Reaction of catechols with *gem*-dihalides has been our approach to satisfying the above criteria. Reaction of 9,9-dibromofluorene (DBF) with catechol leads to a spiro fused ring system that contains a ketal functional group (Figure 2). This reaction proceeds in good in the presence of anion exchange resins to produce the ketal product. Unfortunately, the ketal product displayed no measurable fluorescence. Interaction of lone pair electrons from the ketal oxygens with the fluorene ring system may be responsible for the fluorescence quenching.

The facile reaction of catechol with DBF led us to try other activated, fluorescent *gem*-dihalides for catechol derivation. Methylene groups located between two carbonyls are easily brominated to produce *gem*-dibromides. Investigations into the reactivity of these *gem*-dibromides with catechol were

done using ethyl α,α -dibromomalonate as a probe. Exploring several different combinations of base and solvent, it was found that reaction of α,α -dibromomalonate with catechol in the presence of Cs_2CO_3 (or CsF) in *N,N*-dimethylformamide (DMF) led to high yields of the ketal product (Figure 3). The reaction is complete after 20 minutes at room temperature. Since various esters of the malonate core could be synthesized from malonic acid, we chose this *gem*-dihalide system to build an appropriate fluorescence probe for CE.

The commercially available 9-fluorenylmethanol was mixed with malonic acid in toluene in the presence of *p*-toulenesulfonic acid. Dean-Stark removal of water over 24 h led to the difluorenyl ester, bis-(9-methylenefluorenyl) malonate (Scheme 1). This ester was brominated in chloroform using pyridinium bromide perbromide and triethylamine to produce bis-(9-methylenefluorenyl) α,α -dibromomalonate (Scheme 1). Reaction of bis-(9-methylenefluorenyl) α,α -dibromomalonate with catechol, using the reaction conditions presented above, led to a ketal product that displayed fluorescence not at the usual 315 nm emission of fluorene, but instead displayed a red-shifted emission at 455 nm (Figure 4). This longer wavelength emission also displayed a lower quantum yield than the fluorene parent compound indicating quenching of the fluorophore had occurred.

Investigation into the fluorescent behavior of catechols derived from bis-(9-methylenefluorenyl) α,α -dibromomalonate was done by submitting the compounds to low temperature FLNS. Both catechol and 4-OHE₁ were derivatized with bis-(9-methylenefluorenyl) α,α -dibromomalonate, the products separated by HPLC, and the corresponding HPLC fractions sent to Ryszard Jankowiak at Iowa State University for FLNS analysis. Fluorescence spectra of the two derivatives at 77K shows that their emission spectra differ in the 450 nm region (Figure 5). This indicates that malonate fluorophores could be developed such that FLNS could distinguish differing environments of the catechol A ring. CE metabolites and CE-DNA adducts contain significant differences in substitution at the catechol A ring. Thus, these malonate probes should be useful for structure identification based on authentic standards.

The reduced fluorescence emission from the bis-(9-methylenefluorenyl) α,α -dibromomalonate derived catechols could be the result of fluorescence resonance energy transfer (FRET). FRET occurs when the emission frequency of one molecule overlaps with the absorption frequency of another, near-by molecule [10]. The emission spectrum of fluorene is centered around 315 nm, this is close to the adsorption maximum of 280 nm for catechol. The resulting emission of the derived products at 455 nm indicates interaction between the catechol ring and fluorene. Bis-(9-methylenefluorenyl) malonate, the precursor ester that contains no catechol structure at the α carbon, displays fluorescent properties very similar to fluorene. The incorporation of a catechol ring, with catechol or 4-OHE₁ derivation, leads to a red-shift in the emission to 455nm perhaps as the result of extended conjugation between the two fluorene rings through the catechol ring. Other factors such as π - π interactions have not been ruled out.

In order to test the hypothesis the reduced quantum yields and red-shift of the emission is due to a FRET phenomenon, we plan to change the fluorophore on the malonate ester core to longer wavelength emitters. Anthracene, coumarin, and pyrene fluorophores all have emission spectra close to 400 nm, well separated from the 280 nm absorption of catechol. We have synthesized bis-(9-methyleneanthranthryl) α,α -dibromomalonate. The synthesis of the anthracene probe required a new synthetic methods since bromination of the bis-(9-methyleneanthranthryl) malonate ester resulted in an unknown product probably due to bromination of the anthracene ring system (Scheme 2). Thus, bromination of malonic acid, followed by ester formation with 9-(chloromethylene)anthracene produced bis-(9-methyleneanthranthryl) α,α -dibromomalonate in good yield. We are currently reacting this probe with catechol and CE to establish the fluorescence properties of the derivatized products. Using other known probes for carboxylic acids, we are modifying α,α -dibromomalonate with coumarin and pyrene ring systems. These ester probes will use to form CE derivatives and their spectra will be analyzed using FLNS.

KEY RESEARCH ACCOMPLISHMENTS:

- Establishment of reaction conditions needed to couple catechols with α,α -dibromomalonate esters.
- Synthesis of bis-(9-methylenefluorenyl) α,α -dibromomalonate and derivation of catechol and 4-OHE₁ with this new fluorescent probe.
- Synthesis of bis-(9-methyleneanthranyl) α,α -dibromomalonate.

REPORTABLE OUTCOMES:

- 1) Poster presentation, "Fluorescent Probes for Catechol Estrogens Using Esters Of α,α -Dibromomalonate", Era of Hope Meeting, Atlanta Georgia, June 9, 2000.
- 2) Two Undergraduates, Clark Diffendaffer and Nicole Burns were employed full time during the summer of 1999 and during the academic year 1999/2000. Their training in synthetic processes and analytical procedures not only provided for summer and part-time academic year employment, but also furthered their academic goals relating to careers in health care and cancer research.

CONCLUSIONS:

In order to produce an analytical assay capable of measuring endogenous levels of CE-DNA adducts, fluorescent probes specific for CE estrogens are needed. A successful design for these fluorescent probes would allow for CE-DNA detection at the femtomolar level. This requires the probe be selective for the catechol ring system. Since the catechol ring system contains vicinal, weakly nucleophilic oxygens, probes based on reactive gem-dihalides would allow for selective coupling of the catechol ring to the probe. Thus, design of fluorescent probes containing reactive gem-dihalides has been a central focus of our research.

Reaction of 9,9-dibromofluorene with catechol occurs in high yield, at room temperature, in DMF to produce a ketal product. The resulting spiro ring system displayed no measurable fluorescence. It was discovered that α,α -dibromomalonates also react with catechol in high yield in DMF in the presence of Cs₂CO₃. The incorporation of various fluorescent groups into the malonate core was explored to produce fluorescent probes for catechol and CE.

Bis-(9-methylenefluorenyl) α,α -dibromomalonate was synthesized from 9-fluorenylmethanol and malonic acid in two steps. This new malonate probe reacts with catechol to produce a fluorescent product that displays a red-shift emission (455 vs. 315 nm) with respect to the fluorene fluorophore. This longer wavelength emission displays reduced sensitivity when compared to fluorene; however, the interaction of the catechol ring system with the fluorene ring system could allow for product identification via FLNS. FLNS spectra of both catechol and 4-OHE₁ derivatives of bis-(9-methylenefluorenyl) α,α -dibromomalonate displayed spectral differences in the 450 nm region indicating that fluorescent probes based on fluorescent malonate esters could be used to identify CE-DNA adducts using FLNS.




In order to increase the sensitivity of fluorescent malonate esters, longer wavelength emitters were incorporated. Bis-(9-methyleneanthranyl) α,α -dibromomalonate was synthesized from 9-(chloromethylene)anthracene and malonic acid in three steps. The reaction of this probe with catechol and CE is ongoing and will be the focus of future work in the coming year.


The production of a viable analytical assay that can measure DNA damage caused by estrogen metabolites is an important first step in establishing biomarkers for early breast cancer detection. With

the development of this new assay, one can seek to establish a link between the production of CE-DNA adducts and the onset of breast cancer. If this link were established, biomarkers for the early detection of breast cancer would be at hand. In addition, as new analytical tools for measuring various estrogen metabolites develop, the role of CE estrogen metabolism, as it relates to breast cancer etiology, will become more clearly understood. This could lead to strategies aimed at preventing breast cancer.

REFERENCES:

- 1) Liehr, J.G. (1990) Genotoxic effects of estrogens. *Mutat. Res.*, 238, 269-276.
- 2) Dwivedy, I., Devanesan, P.D., Cremonesi, P., Rogan, E.G., and Cavalieri, E.L. (1992) Synthesis and characterization of estrogen 2,3- and 3,4-quinones. Comparison of the DNA adducts formed by the quinones versus horseradish peroxidase-activated catechol estrogens. *Chem. Res. Toxicol.*, 5, 828-833.
- 3) Stack, D., Byun, J., Gross, M.L., Rogan, E.G., and Cavalieri, E.L. (1996) Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. *Chem. Res. Toxicol.*, 9, 851-859.
- 4) Cavalieri, E., Stack D., Devanesan, P., Todorovic, R., Dwivedy, I., Higginbotham, S., Johansson, S., Patil, K., Gross, M., Gooden, J., Ramanathan, R., Cerny, R. and Rogan, E. (1997) Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators. *Proc. Natl. Acad. Sci. USA*, 94, 10937.
- 5) Spink, D.C., Eugster, H.P., Lincoln II, D.W., Schuetz, J.D., Schuetz, E.G., Johnson, J.A., Kaminsky, L.S., and Gierthy, J.F. (1992) 17 Beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: A comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. *Arch. Biochem. Biophys.*, 293, 342-348.
- 6) Liehr, J.G., Ricci, M.J., Jefcoate, C.R., Hannigan, E.V., Hokanson, J.A., and Zhu, B.T. (1995) 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: Implications for the mechanism of uterine tumorigenesis. *Proc. Natl. Acad. Sci. U.S.A.* 92, 9220-9224.
- 7) Liehr, J.G., and Ricci, M.J. (1996) 4-Hydroxylation of estrogens as marker of human mammary tumors. *Proc. Natl. Acad. Sci. U.S.A.*, 93, 3294-3296.
- 8) Castagnetta, L.A., Granata, O.M., Arcuri, F.P., Polito, L.M., Rosati, F. and Cartoni, G.P. (1992) Gas chromatography/mass spectrometry of catechol estrogens. *Steroids*, 57, 437-443.
- 9) Wehry, E. L. In *Practical Fluorescence*, 2nd ed.; Guilbault G. G., Ed.; Marcel Dekker, Inc.: New York, 1990; pp 117-120.
- 10) Stryer L. and Haugland L.P. (1967) "Energy Transfer: A Spectroscopic Ruler." *Proc Natl Acad Sci USA* , 58, 719.

APPENDICES:**Figure 1. Structural features of a successful fluorescent probe.****Figure 2. Catechol derivative of 9,9-dibromofluorene.****Figure 3. Catechol derivative of ethyl α,α -dibromomalonate.**

**Scheme 1: Synthesis and reaction of bis-(9-methylenefluorenyl) α,α -dibromomalonate**




Figure 4. Chromatograph using UV detection (top) and fluorescence detection (bottom) of catechol derived with bis-(9-methylenefluorenyl) α,α -dibromomalonate.









Figure 5. Low-temperature fluorescence spectra (77K) of catechol and 4-OHE₁ derivatives.

**Route 1:****Route 2:****Scheme 2. Synthesis of bis-(9-methyleneanthranyl) α,α -dibromomalonate.**



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MD 21702-5012

REPLY TO
ATTENTION OF

MCMR-RMI-S (70-1y)

10 Jun 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl

PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB270849
ADB263653
ADB282255
ADB262232
ADB277418
ADB285664
ADB281628
ADB284965
ADB265796
ADB282152
ADB285670
ADB257200
ADB266081
ADB285703
ADB285699
ADB285481
ADB285668
ADB283633